For Forest, Two Launches And Two Filings Planned In 2011 As Patent Cliff Looms
This article was originally published in The Pink Sheet Daily
Executive Summary
On the heels of a strong quarter, Forest has launched the antibiotic Teflaro and plans to introduce the oral COPD candidate Daxas, later this year pending FDA approval.
You may also be interested in...
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.
AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.